Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.87)
# 1,744
Out of 4,670 analysts
24
Total ratings
45.45%
Success rate
0.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $114.23 | +48.82% | 9 | Nov 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $65 | $22.05 | +194.78% | 2 | Aug 26, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $7.84 | +155.10% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $190.40 | +8.19% | 1 | Aug 12, 2024 | |
| CABA Cabaletta Bio | Maintains: Outperform | $25 → $15 | $1.87 | +702.14% | 1 | Aug 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $62 → $66 | $44.73 | +47.55% | 2 | Aug 8, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $478 → $533 | $605.92 | -12.03% | 3 | Jul 12, 2024 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $3.80 | +478.95% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $4.25 | +135.29% | 1 | May 30, 2023 | |
| ABBV AbbVie | Maintains: Outperform | $159 → $165 | $176.95 | -6.75% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $14.08 | +326.14% | 1 | Oct 5, 2022 |
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $114.23
Upside: +48.82%
Jasper Therapeutics
Aug 26, 2024
Maintains: Outperform
Price Target: $65
Current: $22.05
Upside: +194.78%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $7.84
Upside: +155.10%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $190.40
Upside: +8.19%
Cabaletta Bio
Aug 12, 2024
Maintains: Outperform
Price Target: $25 → $15
Current: $1.87
Upside: +702.14%
Mirum Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $62 → $66
Current: $44.73
Upside: +47.55%
argenx SE
Jul 12, 2024
Maintains: Outperform
Price Target: $478 → $533
Current: $605.92
Upside: -12.03%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $3.80
Upside: +478.95%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $4.25
Upside: +135.29%
AbbVie
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $176.95
Upside: -6.75%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $14.08
Upside: +326.14%